RYTM רווח נקי למניה ב-12 החודשים האחרונים rhythmtx.com
The rolling 12-month EPS chart illustrates profit dynamics, where the current value stands at -2.92. This trend confirms the status of Rhythm Pharmaceuticals (RYTM) as an innovator in the treatment of rare forms of obesity trusted by patients. The company dominates a narrow orphan drug segment protected by patents. To achieve efficient growth, the business relies on outsourcing drug production to external contract partners.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_RYTM_-_Rhythm-Pharmaceuticals_-_Earnings-per-share-for-the-last-four-quarters "Rhythm Pharmaceuticals Inc - רווח נקי למניה (EPS TTM) RYTM (תקופה 04.07.2022 - 12.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Rhythm Pharma (RYTM)
Scaling the production of peptide drugs through the validated capacities of CMO partners directly determines the profit trajectory of Rhythm Pharmaceuticals (RYTM). By analyzing the trend of rolling net income per share, an investor assesses the overall business efficiency, where total annual net profit is divided by the number of common shares, allowing for the identification of real equity income and an assessment of capital freeze risks.
